Thromboxane (TXA₂) activates the T prostanoid (TP) receptor. Prostaglandin E₂ (PGE₂) activates four E prostanoid (EP) receptors, EP_1-4. AH-23848 is a dual antagonist of TP1 and EP₄ receptors. It originally was found to inhibit TXA2-induced platelet aggregation (IC₅₀ = 0.26 μM) and the contraction of human bronchial smooth muscle induced by the TP agonist U-46619. AH-23848 was subsequently demonstrated to impair PGE₂-mediated relaxation of piglet saphenous vein by antagonizing the PGE₂ receptor EP₄. Through inhibiting EP₄, it likewise suppresses serum-induced cAMP generation, cyclin A synthesis, as well as the proliferation of fibroblasts, as well as reduces metastasis in a murine model of metastatic breast cancer.

An activator of T prostanoid receptor

Store at -20° C

Solid

TXA2-induced platelet aggregation: IC₅₀ = 0.26 µM

Soluble in DMSO (~5 mg/ml).